Anti‐S100A4 monoclonal antibody treatment ameliorates experimental skin fibrosis and SSc‐specific transcriptional signatures in human skin: Comment on the targeting S100A4 is helpful in SSc treatment by Trinh‐Minh et al

Arthritis & RheumatologyEarly View Letters Anti-S100A4 monoclonal antibody treatment ameliorates experimental skin fibrosis and SSc-specific transcriptional signatures in human skin: Comment on the targeting S100A4 is helpful in SSc treatment by Trinh-Minh et al An-Fang Huang, Corresponding Author An-Fang Huang [email protected] orcid.org/0000-0002-3860-8383 Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, ChinaSearch for more papers by this authorWang-Dong Xu, Wang-Dong Xu orcid.org/0000-0001-8276-1249 School of Public Health, Southwest Medical University, Luzhou, Sichuan, ChinaSearch for more papers by this author An-Fang Huang, Corresponding Author An-Fang Huang [email protected] orcid.org/0000-0002-3860-8383 Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, ChinaSearch for more papers by this authorWang-Dong Xu, Wang-Dong Xu orcid.org/0000-0001-8276-1249 School of Public Health, Southwest Medical University, Luzhou, Sichuan, ChinaSearch for more papers by this author First published: 13 February 2024 https://doi.org/10.1002/art.42824 Supported by the National Natural Science Foundation of China (grant 81701606). Author disclosures are available at https://onlinelibrary.wiley.com/doi/10.1002/art.42824. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Supporting Information Filename Description art42824-sup-0001-Disclosureform.pdfPDF document, 905.8 KB Disclosure form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. References 1Trinh-Minh T, Györfi AH, Tomcik M, et al. Anti-S100A4 monoclonal antibody treatment ameliorates experimental skin fibrosis and SSc-specific transcriptional signatures in human skin. Arthritis Rheumatol Published online December 18, 2023. doi:https://doi.org/10.1002/art.42781 10.1002/art.42781 Google Scholar 2Denton CP, Xu S, Zhang F, et al. Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis. Ann Rheum Dis 2023; 82(9): 1205–1217. CASPubMedWeb of Science®Google Scholar 3Tomcik M, Palumbo-Zerr K, Zerr P, et al. S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis. Ann Rheum Dis 2015; 74(9): 1748–1755. 10.1136/annrheumdis-2013-204516 CASPubMedWeb of Science®Google Scholar 4Švec X, Štorkánová H, Trinh-Minh T, et al. S100A4 neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin. Rheumatology (Oxford) 2023:kead295. 10.1093/rheumatology/kead295 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation